Follistatin-344 Research Evidence

The only human evidence connecting follistatin to muscle improvement comes from Mendell et al. (2015, Molecular Therapy), a gene-therapy trial in 6 Becker muscular dystrophy patients, a virus delivering the follistatin *gene* directly into muscle tissue, a one-time genetic intervention. 4 of 6 patients walked farther on a 6-minute walk test. This is fundamentally different from injecting the follistatin *peptide* itself, which is what research vendors actually sell.

Follistatin-344 has no FDA-approved indication and is not approved for human consumption. It is sold exclusively as a research-grade compound (RUO), and, importantly, the injectable peptide product itself has no published human studies at any dose. This is one of the largest gaps between marketing claims and actual product-specific evidence among compounds in this catalog. Researchers and users should verify the legal status of follistatin-344 in their jurisdiction and weigh this evidence gap carefully.